Phase 1 , randomized, double-blind, placebo-controlled, single-ascending-dose study of PHA12 in healthy subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deucrictibant (Primary)
Indications Hereditary angioedema
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept

07 Oct 2022 According to Phavaris media release, data from this study presented at the 2022 HAEi Global Leadership Workshop
01 Mar 2021 Results from two double-blind placebo-controlled single ascending dose studies presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
18 Nov 2020 According to a Pharvaris media release, the company expects to complete Phase 1 assessments in healthy volunteers at the end of the year and anticipate announcing top-line data in 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com